Dustin S. Sjuts - Aug 11, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: President
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Aug 11, 2023
Transactions value $: -$168,318
Form type: 4
Date filed: 8/15/2023, 04:15 PM
Previous filing: Jul 5, 2023
Next filing: Dec 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Award	$0	+22.6K	+15.25%	$0.00	171K	Aug 11, 2023	Direct	F1
transaction	RVNC	Common Stock	Tax liability	-$168K	-8.9K	-5.21%	$18.91	162K	Aug 11, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date.
F2	Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA.

Content

Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date.

Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA.